Ansa Biotechnologies develops a novel DNA synthesis technology based on enzymes.
Ansa Biotechnologies has raised $45.2M in total funding. The most recent round was Series B. The last funding was announced in October 2025.
Ansa Biotechnologies's investors include RA Capital Management, Y Combinator, National Science Foundation, Fifty Years, Black Opal Ventures.
Ansa Biotechnologies is headquartered in Emeryville, United States.
Ansa Biotechnologies develops a novel DNA synthesis technology based on enzymes.
Ansa Biotechnologies is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ansa Biotechnologies — Funding & Investors." VCBacked, October 1, 2025, https://www.vcbacked.co/company/ansa-biotechnologies. Accessed July 20, 2026.
VCBacked. (2025). Ansa Biotechnologies — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/ansa-biotechnologies
{{cite web |title=Ansa Biotechnologies — Funding & Investors |url=https://www.vcbacked.co/company/ansa-biotechnologies |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated